De Smet P A
Pharmaceutical Care Unit, Scientific Institute Dutch Pharmacists, The Hague, The Netherlands.
Drugs. 1997 Dec;54(6):801-40. doi: 10.2165/00003495-199754060-00003.
Many of our present medicines are derived directly or indirectly from higher plants. While several classic plant drugs have lost much ground to synthetic competitors, others have gained a new investigational or therapeutical status in recent years. In addition, a number of novel plant-derived substances have entered into Western drug markets. Clinical plant-based research has made particularly rewarding progress in the important fields of anticancer (e.g. taxoids and camptothecins) and antimalarial (e.g. artemisinin compounds) therapies. In addition to purified plant-derived drugs, there is an enormous market for crude herbal medicines. Natural product research can often be guided by ethnopharmacological knowledge, and it can make substantial contributions to drug innovation by providing novel chemical structures and/or mechanisms of action. In the end, however, both plant-derived drugs and crude herbal medicines have to take the same pharmacoeconomic hurdle that has become important for new synthetic pharmaceuticals.
我们目前使用的许多药物直接或间接来源于高等植物。虽然几种经典的植物药在与合成药物的竞争中已失去了很多优势,但其他一些植物药近年来却获得了新的研究或治疗地位。此外,一些新型的植物源物质已进入西方药品市场。基于植物的临床研究在抗癌(如紫杉烷类和喜树碱类)和抗疟疾(如青蒿素类化合物)治疗等重要领域取得了特别丰硕的成果。除了纯化的植物源药物外,粗制草药也有巨大的市场。天然产物研究常常可以由民族药理学知识来引导,并且通过提供新的化学结构和/或作用机制,它能够为药物创新做出重大贡献。然而,最终植物源药物和粗制草药都必须跨越同样的药物经济学障碍,这一障碍对于新型合成药物来说已变得至关重要。